UNSPSC 51342803: Delavirdine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C22H28N6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DOL5F9JD3E, chemically known as piperazine, 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1h-indol-2-yl)carbonyl)- but generally known as delavirdine, which bears US NIH Compound Identifier 5625. European Medicines Agency schedules Delavirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06949MIG.

UNSPSC 51342803 Delavirdine is a Commodity code that nominally designates a single pharmaceutical product, but recent state and local opportunities tagged with this code show minimal relevant activity. The code's abstract scope—a specific antiretroviral medication—diverges sharply from the actual solicitations appearing under it. Of the four recent opportunities captured, one (Seminole County's naloxone and drug deactivation systems procurement) involves completely different pharmaceutical products; another (Texas HHS's Therapeutic Pharmacy Initiative RFI) addresses direct-to-manufacturer prescription programs without naming specific drugs; a third (City of Tampa's medical and first aid supplies bid) covers emergency-response consumables for fire rescue; and the fourth (Minnesota MMCAP's generic multi-source pharmaceuticals RFP) addresses bulk pharmaceutical contracting through wholesalers across multiple jurisdictions. None of these solicitations explicitly procure delavirdine or reference the drug by name.

The code shows no concentrated activity among repeat buyers, no clear geographic focus, and no evidence of state or local procurement specifically targeting delavirdine as a line item. Issuing bodies span a county health department (Seminole County, Florida), a state health authority (Texas HHS), a city fire department (Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP serving multiple jurisdictions including Oregon). The mismatch between the code's nominal scope and the actual work being bought suggests either miscoding by issuing bodies or that delavirdine procurement through state and local channels is too fragmented or infrequent to generate relevant solicitation activity. Vendors pursuing this code should verify whether recent opportunities are genuinely seeking delavirdine or represent tagging errors before allocating business development resources.